Navigation Links
Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases

Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Franchise

SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- Celgene Corporation announced its plans to advance the development of leading oral anti-inflammatory candidates across a broad range of inflammatory diseases. CC-10004 (apremilast), an oral TNF antagonist and anti-inflammatory agent has demonstrated significant activity and an excellent side effect profile in a placebo controlled proof-of-mechanism trial in psoriasis.

The multicenter, randomized, double blind, placebo-controlled Phase II study achieved the primary endpoint after 12 weeks of treatment with 24% of patients receiving CC-10004 twice daily achieving a PASI-75 score compared to 10% of those receiving placebo. The Psoriasis Area and Severity Index (PASI) is a standard measurement of response utilized to assess improvement in patients with moderate to severe psoriasis. In addition, 57% of patients receiving CC-10004 twice daily achieved a PASI-50 compared to 23% of those receiving placebo. Most importantly, patients receiving CC-10004 continued to improve over time.

"The data from the Phase II study in patients with moderate-to-severe psoriasis are clinically and statistically significant compared with placebo. In addition, patients continued to improve throughout the 12 week treatment regimen with an oral therapy that has a good side effect profile addressing an unmet medical need," said Alice Gottlieb, M.D., Ph.D., Dermatologist in Chief and Chair, Department of Dermatology of Tufts-New England Medical Center. "The PASI-90 response of 14% for CC-10004 is comparable to Enbrel dosed at 25 mg twice weekly."

Based on these results, Celgene is accelerating clinical and regulatory strategies for CC-10004 in psoriasis, psoriatic arthritis, rheumatoid arthritis and other inflammatory diseases. The Company is also initiating development plans to a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/3/2015)... Aug. 4, 2015   The Intellectual Property ... world,s leading provider of intelligent information for businesses ... 2015 CMR Pharmaceutical R&D Factbook , the biopharmaceutical ... concerns around declines in R&D, the analysis identifies ... trillion milestone and forecasts sales to reach $1.3 ...
(Date:8/3/2015)... WARRINGTON, Pa. , Aug. 3, 2015 /PRNewswire/ ... a specialty biotechnology company focused on developing aerosolized ... a live teleconference and webcast at 8:30 a.m. Eastern ... time management will discuss the 2015 second quarter ... The company will issue a press release announcing ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Pharma Sales to Grow Beyond $1 Trillion 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2
... Perceptive Informatics, the industry,s leading eClinical solutions provider ... PRXL ), today announced the results ... entitled "Optimizing Adaptive Trial Designs: Using Simulation ... by Perceptive Informatics with partner Cytel Inc., a ...
... Pharmaceuticals announced today positive results from its clinical ... Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis.Prednisporin(TM) ... profile (no increase in intra-ocular pressure) than PredForte(TM), ... dose of prednisolone acetate, in patients treated for ...
Cached Medicine Technology:Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 2Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 3Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 4Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 5Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 2Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
(Date:8/4/2015)... ... 2015 , ... Updated enrollment data on the top U.S. health plans, as ... at http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. ... charts on the website’s “Data” section include:, , Top 25 ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a three year clinical ... rare eye disease that progressively causes blindness, were published on June 23, 2015 in ... results of the trial, the implant, more commonly known as the “bionic eye,” is ...
(Date:8/4/2015)... Miramar Beach, FL (PRWEB) , ... August 04, 2015 , ... ... people are living with psoriatic disease and its uncomfortable symptoms such as dry, itching, ... suffer from psoriasis bounce from medication to medication before they find what’s right for ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... 20 finalists for America’s Favorite Veterinarian. The contest is put on by the ... committee from 500 nominees. Nominees were evaluated on community involvement, ethical behavior, passion ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3
... Increases 32% to $14.2 Million ... Sets Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, ... products and services, today reported financial results for the,fourth quarter ... was $14.2 million, up 32.4% from $10.7 million reported in ...
... exhalations hint at wide range of conditions , , ... that uses laser light to sample a person,s breath ... number of diseases, a U.S. study says. , This ... one day help doctors screen patients for diseases such ...
... drugs is a worry, study says, , , MONDAY, Feb. 25 ... advanced dementia are given antibiotics in the last two weeks ... is whether or not that therapy has any benefits, such ... And, of concern are the risks associated with antibiotic use, ...
... Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a California based ... to $100M dollars in face value, of which ... ... CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD). MaxLife ...
... A sophisticated robotic dog could be a good companion ... living pet, a new Saint Louis University study suggests. ... homes interacted with Sparky, a living, medium-sized gentle mutt, ... that looks like a three-dimensional cartoon. , The most ...
... Metalsmith Michael Aram,will lend his support to another noteworthy ... doors to his flagship store on March,13th for a special ... New Delhi based charity that was,established in 1994, at a ... Foundation has committed itself to raising awareness on and,preventing the ...
Cached Medicine News:Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Laser Screen Detects Diseases in Breath 2Health News:Antibiotic Use in Dementia Patients Questioned 2Health News:Antibiotic Use in Dementia Patients Questioned 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3Health News:Faux Fido eases loneliness in nursing home residents as well as real dog, SLU study finds 2
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
Penfield Watchmaker Forceps. Tip width 0.9 mm....
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: